Stifel Nicolaus Issues Positive Forecast for Oruka Therapeutics (NASDAQ:ORKA) Stock Price

Oruka Therapeutics (NASDAQ:ORKA) had its target price upped by Stifel Nicolaus from $47.00 to $72.00 in a research report report published on Friday,Benzinga reports. They currently have a buy rating on the stock.

Several other equities analysts have also commented on ORKA. Guggenheim reiterated a “buy” rating and issued a $60.00 target price on shares of Oruka Therapeutics in a research note on Friday. Weiss Ratings reissued a “sell (d-)” rating on shares of Oruka Therapeutics in a research note on Thursday, January 22nd. Piper Sandler started coverage on Oruka Therapeutics in a report on Thursday, December 18th. They issued an “overweight” rating and a $75.00 price target for the company. BTIG Research upped their price objective on shares of Oruka Therapeutics from $63.00 to $73.00 and gave the company a “buy” rating in a research note on Monday, January 12th. Finally, Wall Street Zen lowered shares of Oruka Therapeutics from a “hold” rating to a “sell” rating in a report on Sunday, March 8th. Nine investment analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $56.67.

Oruka Therapeutics Stock Performance

Shares of ORKA opened at $40.00 on Friday. Oruka Therapeutics has a fifty-two week low of $5.49 and a fifty-two week high of $41.19. The company has a market capitalization of $1.94 billion, a PE ratio of -21.51 and a beta of -0.38. The stock has a fifty day moving average of $32.92 and a two-hundred day moving average of $27.50.

Oruka Therapeutics (NASDAQ:ORKA) last issued its quarterly earnings results on Thursday, March 12th. The company reported ($0.45) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.61) by $0.16. As a group, equities research analysts forecast that Oruka Therapeutics will post -3.41 earnings per share for the current fiscal year.

Insider Buying and Selling at Oruka Therapeutics

In other news, insider Joana Goncalves sold 7,000 shares of the firm’s stock in a transaction dated Tuesday, February 17th. The stock was sold at an average price of $32.37, for a total transaction of $226,590.00. Following the completion of the sale, the insider directly owned 34,018 shares in the company, valued at $1,101,162.66. This trade represents a 17.07% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Insiders sold 21,000 shares of company stock worth $663,530 in the last three months. 24.69% of the stock is owned by company insiders.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently bought and sold shares of the business. Goldman Sachs Group Inc. acquired a new stake in Oruka Therapeutics during the 1st quarter valued at approximately $2,505,000. Geode Capital Management LLC increased its holdings in Oruka Therapeutics by 100.6% during the 2nd quarter. Geode Capital Management LLC now owns 707,406 shares of the company’s stock worth $7,932,000 after purchasing an additional 354,821 shares during the last quarter. Police & Firemen s Retirement System of New Jersey acquired a new position in shares of Oruka Therapeutics in the 2nd quarter valued at approximately $68,000. Intech Investment Management LLC acquired a new position in shares of Oruka Therapeutics in the 2nd quarter valued at approximately $168,000. Finally, JPMorgan Chase & Co. boosted its stake in shares of Oruka Therapeutics by 567.7% during the 2nd quarter. JPMorgan Chase & Co. now owns 15,425 shares of the company’s stock valued at $173,000 after buying an additional 13,115 shares during the last quarter. Hedge funds and other institutional investors own 56.44% of the company’s stock.

Oruka Therapeutics News Roundup

Here are the key news stories impacting Oruka Therapeutics this week:

• Positive Sentiment: Multiple brokerages raised or reaffirmed bullish ratings and lifted price targets (signals of stronger buy-side conviction and potential re-rating of the stock). Benzinga
• Positive Sentiment: Barclays raised its price target to $50 and set an “overweight” rating, implying meaningful upside from current levels. Benzinga
• Positive Sentiment: BTIG reiterated a “buy” and kept a $73 price target, the highest among recent notes, which can attract momentum investors. Benzinga Street Insider
• Positive Sentiment: Stifel Nicolaus raised its target to $72 and maintained a “buy,” reinforcing analyst consensus around significant upside. Benzinga
• Positive Sentiment: Guggenheim reaffirmed a “buy” with a $60 target and Wedbush kept an “outperform” at $45 — additional corroboration from the sell-side. Benzinga
• Positive Sentiment: Oruka reported Q4 results with EPS of ($0.45), beating consensus (($0.61)), which reduces short‑term execution risk and supports the bullish analyst activity. Press Release
• Positive Sentiment: Corporate update: ORKA-001 (EVERLAST-A) 16‑week data now expected in 2Q 2026 after rapid enrollment, with longer-term follow-up in 2H 2026 — an accelerated clinical timetable is a near-term catalyst for valuation. GlobeNewswire

About Oruka Therapeutics

Oruka Therapeutics, Inc is a clinical‐stage biopharmaceutical company focused on the development of novel peptide‐based therapies for oncology. The company’s proprietary stapled peptide platform is designed to selectively disrupt intracellular protein–protein interactions that drive tumor growth and immune evasion. By combining the specificity of biologics with the cell‐permeability of small molecules, Oruka aims to target cancer pathways that have been historically considered “undruggable.”

The company’s lead candidate, ONCT-01, is currently in Phase 1 clinical trials for patients with advanced solid tumors, assessing safety, tolerability and preliminary efficacy.